(Q39282673)

10 September 2017

Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells (English)

1 reference

10 September 2017

1 reference

1 reference

2

1 reference

10 September 2017

4

1 reference

10 September 2017

8

1 reference

10 September 2017

Pepita Giménez-Bonafé

9

1 reference

10 September 2017

Roser Mir

1

1 reference

10 September 2017

Fina Martinez-Soler

3

1 reference

10 September 2017

Enric Condom

5

1 reference

10 September 2017

Alba Pérez-Perarnau

6

1 reference

10 September 2017

Tatiana Ruiz-Larroya

7

1 reference

10 September 2017

language of work or name

English

0 references

publication date

11 October 2012

1 reference

International Journal of Cancer

10 September 2017

12

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

10 September 2017

132

1 reference

10 September 2017

7

1 reference

10 September 2017

1525-1536

1 reference

Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies

10 September 2017

1 reference

21 January 2018

Surfing the p53 network

1 reference

Live or let die: the cell's response to p53

21 January 2018

1 reference

Inhibiting the p53-MDM2 interaction: an important target for cancer therapy

21 January 2018

1 reference

p53 Activation by small molecules: application in oncology

21 January 2018

1 reference

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

21 January 2018

1 reference

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

21 January 2018

1 reference

Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.

21 January 2018

1 reference

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme

21 January 2018

1 reference

p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma

21 January 2018

1 reference

Platinum neurotoxicity pharmacogenetics

21 January 2018

1 reference

Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways

21 January 2018

1 reference

Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin

21 January 2018

1 reference

Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.

21 January 2018

1 reference

Aqueous extract of herba Scutellaria barbatae, a chinese herb used for ovarian cancer, induces apoptosis of ovarian cancer cell lines

21 January 2018

1 reference

Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells

21 January 2018

1 reference

Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins

21 January 2018

1 reference

Hydroxyl radical mediates cisplatin-induced apoptosis in human hair follicle dermal papilla cells and keratinocytes through Bcl-2-dependent mechanism

21 January 2018

1 reference

Survivin as a global target of intrinsic tumor suppression networks

21 January 2018

1 reference

Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells

21 January 2018

1 reference

Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo.

21 January 2018

1 reference

Survivin, versatile modulation of cell division and apoptosis in cancer

21 January 2018

1 reference

Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo

21 January 2018

1 reference

Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation

21 January 2018

1 reference

FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5.

21 January 2018

1 reference

Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer

21 January 2018

1 reference

Targeting survivin in cancer therapy

21 January 2018

1 reference

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

Temporal dissection of tumorigenesis in primary cancers

21 January 2018

1 reference

ARID1A mutations in endometriosis-associated ovarian carcinomas

21 January 2018

1 reference

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

21 January 2018

1 reference

Pharmacologic activation of p53 by small-molecule MDM2 antagonists

21 January 2018

1 reference

Recent advances in the therapeutic perspectives of Nutlin-3.

21 January 2018

1 reference

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.27832

1 reference

10 September 2017

1 reference